International Isotopes Inc. Financial Overview
International Isotopes Inc. (OTCQB: INIS), headquartered in Idaho Falls, has shared its financial outcomes for the third quarter and the first nine months of the fiscal year 2025. The company's recent report highlights significant developments in their financial performance, discussing both challenges and growth opportunities within their operational segments.
Third Quarter and Year-to-Date Results
In the third quarter of 2025, the revenue generated from product sales reached $3,277,816. This amount reflects a decrease of $646,628, or 16%, compared to the third quarter of 2024. In contrast, for the nine months ended in September 2025, the total revenue stood at $10,172,036, which is an increase of $173,901, or 2%, from the same period last year. Notably, the company reported a net loss of $203,601 for the third quarter of this fiscal year, contrasting with a net profit of $150,251 in the same quarter last year. Similarly, the first nine months revealed a net loss of $477,080, which was an increase in losses by $237,245 from the previous year.
Impact of Raw Material Outages
The declines in revenue for both the quarter and the nine-month period were attributed largely to outages of critical raw materials for Theranostics Products and Calibration & Reference Products earlier in the year. The company estimates that these outages led to a revenue decrease of over $400,000 for the third quarter and more than $750,000 year-to-date. These challenges have had a significant influence on the company's product segments, particularly with their Theranostics and Calibration offerings.
Management's Comments on Raw Material Challenges
Shahe Bagerdjian, the President & CEO, noted the significant challenges the company faced due to raw material outages, particularly for Theranostics products. He emphasized the disruption caused by the limited availability of Gadolinium-153, which is essential for Calibration Products. Despite these struggles, the company successfully expanded its customer base for Theranostics during the quarter, showcasing resilience and adaptability.
Company's Strategic Improvements
Efforts undertaken during the quarter focused on enhancing internal operations. Management reported a 24% reduction in selling, general, and administrative (SG&A) costs for the quarter, contributing to improved operational efficiency. Moreover, ongoing development in the Calibration and Reference Products segment has seen both improvement in legacy products and the introduction of several new offerings, solidifying their market position.
Segment Performance Highlights
Theranostics Products
During the first nine months of 2025, revenue from Theranostics Products totaled $5,176,740, down from $6,257,410 in the previous year, reflecting a 17% decrease. This decline primarily resulted from supply constraints related to I-131 raw materials, particularly during the early quarters. However, the approval of a new supplier in September, coupled with rising demand for sodium iodide I-131 products, provides a hopeful outlook for future growth in this segment.
Calibration & Reference Products
In a positive turn, the first nine months of 2025 witnessed a surge in revenue for Calibration & Reference Products which climbed to $3,301,673, up 57% from $2,099,713 last year. This growth can be attributed to the resolution of previous shortages concerning Cobalt-57 isotope, enhancing product availability and driving sales.
Cobalt and Medical Device Revenue
Revenue from Cobalt Products for the first nine months was $1,517,147, reflecting an 8% decrease from $1,641,012 in the prior year. This variance is primarily tied to seasonal fluctuation in sales. In contrast, the new Medical Devices segment, introduced last fiscal year, reported $176,476 in sales, marking a strong entry into the market with products designed to enhance safety and access to radiopharmaceuticals.
Looking Forward
As the company moves ahead, it anticipates a stabilization in supply chains which will influence revenue for the year positively. There are expectations for consistent growth across all segments, particularly in Calibration and Medical Devices as they continue to innovate and address market needs effectively. Ongoing efforts in corporate governance, including enhancing board oversight and new committee formations, underline the company’s commitment to robust operational execution.
Frequently Asked Questions
What were the main factors affecting the revenue of International Isotopes Inc.?
The company faced significant revenue declines primarily due to outages of critical raw materials necessary for their Theranostics and Calibration Products.
How did International Isotopes perform in terms of net profits this quarter?
For the third quarter of 2025, the company reported a net loss of $203,601, down from a net profit of $150,251 in the previous year.
What steps has International Isotopes taken to improve operational efficiency?
Management reported a 24% reduction in SG&A costs for the quarter, focusing on operational improvements and optimizing existing processes.
What growth opportunities exist for International Isotopes in the future?
The company is poised for growth through improved supply chain stability, expansions in their Theranostics customer base, and ongoing developments in Calibration and Medical Devices.
When was the last time International Isotopes reported a profit?
The last reported profit was in the third quarter of 2024, after which the company has faced net losses in subsequent quarters.
